The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl Borrebaeck

Carl Borrebaeck

Professor

Carl Borrebaeck

Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma

Author

  • Sara Ek
  • Eva Ortega-Paino
  • Carl Borrebaeck

Summary, in English

Mantle cell lymphoma (MCL) is an aggressive malignancy and new treatment modalities must be established to increase patient survival time. In the search for new therapeutic targets, reliable and well-characterised in vitro models are essential. In this study, we have characterised three MCL cell lines (SP53, Granta 519 and NCEB1) in comparison with primary tumors front MCL, follicular lymphomas (FL), a(.)FL cell line(RL), a Burkitt lymphoma cell line (RAJI) and five different B cell populations from healthy individuals. Expression profiling was used to determine the relative expression of >12000 transcripts in these samples, and flow cytometry analysis was performed to establish a phenotypic signature for each of the cell lines. In addition, the cell lines were sequenced, and the frequency of somatic Mutations and immunoglobulin (Ig) variable heavy chain (V-H) Usage were determined. We show by hierarchical clustering that the cell lines retain a genetic signature similar to primary MCL, which readily separated the MCL samples front the other lymphoma cell lines and the FL tumours. Furthermore, the MCL cell lines showed differences in the frequency of V-H somatic mutations (0-2.1%). The increased number of mutations in NCEB1, compared to the other MCL cell lines, was in agreement with a decreased expression of CD31, CD44, CXCR5, CCR7 and CCR6. Taken together, our data show that the cell lines are clearly derived from MCL tumours and expressed similar genetic and phenotypic signatures compared to primary tumours, which confirmed their usefulness as in vitro models. (C) 2004 Elsevier Ltd. All rights reserved.

Department/s

  • Department of Immunotechnology

Publishing year

2005

Language

English

Pages

205-213

Publication/Series

Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis

Volume

29

Issue

2

Document type

Journal article

Publisher

Elsevier

Topic

  • Cancer and Oncology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1873-5835